Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP

BMC Psychiatry

Renate Grohmann¹  Stefan Russmann²  Waldemar Greil³  Anne Haeberle¹ 

[1] Department of Psychiatry, Ludwig Maximilian University, Munich, Germany, Nussbaumstr. 7, Munich, 80336, Germany;Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Raemistrasse 100, Zurich, 8091, Switzerland;Sanatorium Kilchberg, Alte Landstrasse 70, Kilchberg-Zurich, 8802, Switzerland

关键词: Antidepressants;    Psychotropic drugs;    Prescription;    Pharmacotherapy;    Guidelines;    Drug surveillance;    Combination therapy;    Bipolar disorder;    Bipolar depression;    AMSP;   

Others  :  1124278
DOI  :  10.1186/1471-244X-12-153

 received in 2012-04-30, accepted in 2012-09-17,  发布年份 2012

【 摘 要 】

Background

For the pharmacological treatment of bipolar depression several guidelines exist. It is largely unknown, to what extent the prescriptions in daily clinical routine correspond to these evidence based recommendations and which combinations of psychotropic drugs are frequently used.

Methods

The prescriptions of psychotropic drugs were investigated of all in-patients with bipolar depression (n = 2246; time period 1994–2009) from hospitals participating in the drug surveillance program AMSP. For the drug use in 2010, 221 cases were analysed additionally.

Results

From 1994 to 2009, 85% of all patients received more than one class of psychotropic substances: 74% received antidepressants in combination therapy, 55% antipsychotics, 48% anticonvulsants and 33% lithium. When given in combination, lithium is the most often prescribed substance for bipolar depression (33%), followed by valproic acid (23%), mirtazapine and venlafaxine (16% each), quetiapine (15%), lamotrigine (14%) and olanzapine (13%). Both, lithium and valproic acid are often combined with selective serotonin reuptake inhibitors (SSRI), but also with mirtazapine und venlafaxine. Combinations of more than one antidepressant occur quite often, whereby combinations with bupropion, paroxetine, fluoxetine or fluvoxamine are very rare. In 2010, quetiapine (alone and combined) was the most frequently prescribed drug (39%); aripiprazole was administered in 10%.

Conclusion

Combinations of antidepressants (SSRI, mirtazapine, venlafaxine) with mood stabilizers (lithium, valproic acid, lamotrigine) and / or atypical antipsychotics (quetiapine, olanzapine) are common. Of most of those combinations the efficacy has not been studied. The use of aripiprazole and the concomitant use of two or three antidepressants contrast the guidelines.

【 授权许可】

   
2012 Haeberle et al.; licensee BioMed Central Ltd.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Malhi GS, Adams D, Lampe L, Paton M, O'Connor N, Newton LA, Walter G, Taylor A, Porter R, Mulder RT, et al.: Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009, 439:27-46.
• [2]Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S: The world federation of societies of biological psychiatry (WFSBP) Guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010, 11:81-109.
• [3]NICE: Review of Clinical Guidelines (CG38) - Bipolar; the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence, centre for Clinical Practice 2012. http://publications.nice.org.uk/bipolar-disorder-cg38 webcite
• [4]Goodwin GM: Evidence-based guidelines for treating bipolar disorder: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009, 23:346-388.
• [5]Kasper S: International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression. J Clin Psychiatry 2008, 69:1632-1646.
• [6]Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, et al.: Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009, 11:225-255.
• [7]Grohmann R, Engel RR, Ruther E, Hippius H: The AMSP drug safety program: methods and global results. Pharmacopsychiatry 2004, 37(Suppl 1):S4-S11.
• [8]Engel RR, Grohmann R, Ruther E, Hippius H: Research methods in drug surveillance. Pharmacopsychiatry 2004, 37(Suppl 1):S12-S15.
• [9]Greil W, Haberle A, Haueis P, Grohmann R, Russmann S: Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord 2012, 136:534-542.
• [10]Amsterdam JD, Shults J: Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol 2008, 28:171-181.
• [11]Suppes T, Marangell LB, Bernstein IH, Kelly DI, Fischer EG, Zboyan HA, Snow DE, Martinez M, Al JR, Shivakumar G, et al.: A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008, 111:334-343.
• [12]van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MA, Vieta E, et al.: Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70:223-231.
• [13]Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M: A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010, 71:150-162.
• [14]American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159:1-50.
• [15]Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Moller HJ: World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 2002, 3:115-124.
• [16]Haueis P, Greil W, Huber M, Grohmann R, Kullak-Ublick GA, Russmann S: Evaluation of drug interactions in a large sample of psychiatric inpatients: a data interface for mass analysis with clinical decision support software. Clin Pharmacol Ther 2011, 90:588-596.
• [17]Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM: The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000, 61:9-15.
• [18]Goldberg JF, Brooks JO III, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, Miklowitz DJ, Ketter TA, Sachs GS, Thase ME: Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009, 70:155-162.
• [19]Brooks JO III, Goldberg JF, Ketter TA, Miklowitz DJ, Calabrese JR, Bowden CL, Thase ME: afety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry 2011, 72:240-247.
• [20]Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, Bowden CL: Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord 2010, 122:1-9.
• [21]Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, Monaghan ET, Leadbetter RA: Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008, 10:323-333.
• [22]Calabrese JR, Kasper S, Johnson G, Tajima O, Vieta E, Yatham LN, Young AH: International consensus group on bipolar I depression treatment guidelines. J Clin Psychiatry 2004, 65:571-579.
• [23]Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162:1351-1360.
• [24]Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006, 26:600-609.
• [25]McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH: A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010, 71:163-174.
• [26]Suppes T: Effectiveness of the extended release formulation of quetipaine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010, 121:106-115.
• [27]Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs GS, Swann AC: The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005, 66:870-886.
• [28]Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, Sharma V, Beaulieu S: Canadian network for mood and anxiety treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006, 8:721-739.
• [29]Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G: Treatment of bipolar depression: an update. J Affect Disord 2008, 109:21-34.
• [30]Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL: Bipolar depression: overview and commentary. Harv Rev Psychiatry 2010, 18:143-157.
• [31]Ittasakul P, Johnson KR, Srivastava S, Childers ME, Brooks JO III, Hoblyn JC, Ketter TA: Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients. J Affect Disord 2012, 137:139-145.
• [32]Chiesa A, Chierzi F, De RD, Serretti A: Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol 2012, 27:76-90.
• [33]Amsterdam JD, Wang CH, Shwarz M, Shults J: Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial. J Affect Disord 2009, 112:219-230.
• [34]Amsterdam JD, Shults J: Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010, 167:792-800.
• [35]Amsterdam JD, Wang G, Shults J: Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta Psychiatr Scand 2010, 121:201-208.
• [36]Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Kupka RW, Denicoff KD, Nolen WA, Grunze H, et al.: Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006, 163:232-239.
• [37]Altshuler L, Suppes T, Black D, Nolen WA, Keck PE Jr, Frye MA, McElroy S, Kupka R, Grunze H, Walden J, et al.: Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003, 160:1252-1262.
• [38]Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, et al.: Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007, 356:1711-1722.
• [39]Salvi V, Fagiolini A, Swartz HA, Maina G, Frank E: The use of antidepressants in bipolar disorder. J Clin Psychiatry 2008, 69:1307-1318.
• [40]Sidor MM, MacQueen GM: Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011, 72:156-167.
• [41]Amit BH, Weizman A: Antidepressant treatment for acute bipolar depression: an update. Depress Res Treat 2012, 684725.
• [42]Ghaemi SN: Antidepressants in bipolar depression: The clinical debate. Aust.N.Z.J Psychiatry 2012, 46:289-301.